| Name | Title | Contact Details |
|---|
We are committed to providing the best possible climate for development and achievement of goals for all employees. We are an equal opportunity employer and our practice has always been to treat each employee as an individual. We have always sought to
Charolais Connection is a Regina, SK-based company in the Business Services sector.
Trion Solutions is one of the Nation’s leading providers of value-added Human Resources Services. From payroll, to benefits to fully-managed assumed employee programs, Trion Solutions provides programs that help companies conquer the myriad issues and costs of maintaining an effective workforce. For over 12 years Trion Solutions has provided reliable and innovative HR services. Audited by an independent CPA, we consistently maintain the highest industry standards. We offer assistance at every stage of a company’s growth with effective programs, custom tailored to specific needs. Our energetic staff of industry specialists help our customers meet and exceed their employee management goals, as well as regulatory compliance efforts. By embracing leading edge technology, Trion Solutions delivers a greater range of flexible services to companies of any size. From customized reporting, to online administration and self-serve benefit services, to a specialized employee MARKETPLACE, Trion Solutions adds ease and value.
Zorch International, Inc. is a Chicago, IL-based company in the Business Services sector.
Cellerant Therapeutics is a clinical stage biotechnology company focused on developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant`s programs include: CLT-008, an off-the-shelf cellular immunotherapy, under evaluation in a multicenter, open-label, randomized, controlled Phase 2 clinical trial in patients with de novo AML; CSC030-ADC, a preclinical monoclonal antibody drug conjugate that selectively targets and kills leukemic stem and blast cells responsible for initiating and maintaining disease; and CSC012, a preclinical monoclonal antibody targeting leukemic and pre-leukemic stem cells for acute leukemias and myelodysplastic syndromes. The Company is also developing next generation CAR product candidates leveraging its proprietary immunocellular therapy and antibody discovery and development platform.